GlassScriptPhysician profile
Kristin Freeman
NPI 1972796548
$1,247.41
in general payments reported to CMS, 2019-2025
22 companies · $78.41 in 2025
The $78.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $241 · 2021: $221 · 2022: $159 · 2023: $52.05 · 2024: $107 · 2025: $78.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $226.50 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $141.50 | 2019-2024 | Mounjaro |
| Amarin Pharma, INC. | $128.86 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.37 | 2020-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.47 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $91.42 | 2019 | |
| Abbvie INC. | $86.52 | 2021-2022 | |
| Novo Nordisk INC | $63.23 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.86 | 2019-2020 | |
| Daiichi Sankyo INC. | $51.12 | 2020-2024 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $29.05 | 2021 | |
| Inspire Medical Systems, INC. | $21.35 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $20.42 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.75 | 2024 | Fanapt, Hetlioz |
| Paratek Pharmaceuticals, INC. | $18.59 | 2024 | Nuzyra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.34 | 2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $13.08 | 2022 | |
| Allergan, INC. | $12.83 | 2019 | |
| Genentech USA, INC. | $12.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.